ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages ...

Arcutis Biotherapeutics (NASDAQ:ARQT) executives highlighted strong recent commercial performance for ZORYVE and outlined near-term regulatory and pipeline milestones during a presentation and ...

Credit: Arcutis. Zoryve topical foam is a once-daily steroid-free formulation of a highly potent and selective phosphodiesterase type 4 inhibitor. The Food and Drug Administration (FDA) has approved ...

While "seborrheic dermatitis" (seb derm) may not be a household name, one of its most common visible symptoms—flakes that may ...

Please provide your email address to receive an email when new articles are posted on . This decision makes Zoryve the first drug approved in this indication with a new mechanism of action in more ...

Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...

Arcutis Biotherapeutics is going straight to consumers to let them know that Zoryve is The Cream That Can. On Tuesday morning, the early commercial-stage biopharmaceutical company launched its first ...

About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.

Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing innovations in immuno-dermatology, announced the U.S. Food and Drug Administration has approved the ...

Please provide your email address to receive an email when new articles are posted on . Zoryve cream 0.05% is a nonsteroidal, phosphodiesterase 4 inhibitor that has shown efficacy in clinical trials.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 27, 2026, Guggenheim raised its price target on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...